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ABSTRACT 
Background and Purpose 
Mu opioid receptor (µ-receptor) agonists are used for pain management, but produce adverse 
effects including tolerance, dependence, and euphoria. The co-administration of a µ-receptor 
agonist with a delta opioid receptor (δ-receptor) antagonist has been shown to produce 
antinociception with reduced development of some side effects. We characterized the effects of 
three µ-receptor agonist/δ-receptor antagonist peptidomimetics in vivo after acute and repeated 
administration to determine if this profile provides a viable alternative to traditional opioid 
analgesics. 
Experimental Approach 
Three µ-receptor agonist/δ-receptor antagonist peptidomimetics, AAH8, AMB46, and AMB47, 
and morphine were evaluated for the development of tolerance and dependence after five days of 
twice daily treatment with escalating doses of drug (10-50 mg kg-1). Antinociceptive effects were 
measured in the warm water tail withdrawal (WWTW) assay before and after repeated drug 
treatment; physical dependence was evaluated by naltrexone-precipitated withdrawal jumping. 
The rewarding effects of AAH8 were evaluated using a conditioned place preference (CPP) 
assay with twice daily conditioning sessions performed for five days.  
Key Results 
Morphine, AAH8, AMB47, and AMB46 all demonstrated acute antinociceptive effects, but 
repeated administration only produced tolerance in animals treated with morphine and AMB46. 
Injection of naltrexone precipitated fewer jumps in mice treated repeatedly with AAH8 as 
compared with morphine, AMB47, or AMB46. Conditioning with morphine, but not AAH8, 
produced significant CPP.   
Conclusions and Implications 
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AAH8 may be a better alternative than traditional opioid analgesics, producing antinociception 
with less development of tolerance and dependence and may be less rewarding than morphine.  
 
KEY WORDS: Mixed efficacy, mu opioid receptor, delta opioid receptor, tolerance, 
dependence, conditioned place preference, peptidomimetic  
ABBREVATIONS:  [35S]GTPγS, [35S] guanosine 5'-O-[gamma-thio]triphosphate; δ-receptor, 
delta opioid receptor; κ-receptor, kappa opioid receptor; µ-receptor, mu opioid receptor; BID, 
bid in die (twice daily); CPP, conditioned place preference; DAMGO, D-Ala2, N-MePhe4, Gly-
ol]-enkephalin; DPDPE, D-Pen2,5- enkephalin; EDTA, Ethylenediaminetetraacetic acid; MPE, 
maximal percent effect; NLX, naloxone; NTI, naltridnole; NTX, naltrexone; Ke, potency of a 
pure antagonist; Ki, inhibition constant for a ligand; TFA, trifluroacetic acid; TST, tail 
suspension test; w/v, weight to volume; w/w, weight to weight WWTW, warm water tail 
withdrawal; +/+, wildtype; -/-  homozygous knockout. 
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 Introduction  
While opioid drugs have significant clinical utility in treating pain, there are drawbacks 
associated with their chronic use, including tolerance, dependence, constipation, and addiction 
liability (Benyamin et al., 2008). The development of tolerance to the analgesic effects of opioids 
often leads to dose escalation, which may contribute to opioid misuse and abuse (Ballantyne and 
LaForge, 2007). Further, individuals who are dependent on opioids may misuse them to prevent 
withdrawal (Ross and Peselow, 2009, Bailey and Connor, 2005, Johnston et al., 2009, Ballantyne 
and LaForge, 2007). Opioid compounds that produce robust analgesia with limited development 
of tolerance and dependence could address a significant unmet medical need and provide an 
alternative to traditional opioid analgesics to prevent opioid misuse and abuse. 
Opioids produce both their pain-relieving and adverse effects through stimulation of the 
mu opioid receptor (µ-receptor); therefore, creating more selective ligands for the µ-receptor is 
unlikely to reduce the incidence of adverse events. There are reports that the co-administration of 
µ-receptor agonist with a delta opioid receptor (δ-receptor) antagonist produces µ-receptor-
mediated antinociception with reduced tolerance and dependence liabilities (Abdelhamid et al., 
1991, Fundytus et al., 1995, Hepburn et al., 1997, Purington et al., 2009, Schiller, 2009, Anand et 
al., 2016, Váradi et al., 2016) and similar results have been found in δ-receptor knockout animals 
(Zhu et al., 1999). As a result the development of µ-receptor agonist/δ-receptor antagonist 
compounds – mixed efficacy ligands – has been explored and several peptide (Purington et al., 
2011, Purington et al., 2009, Schiller et al., 1999, Schmidt et al., 1994, Anand et al., 2012, Cai et 
al., 2014), peptide-like (Balboni et al., 2002b, Balboni et al., 2002a, Salvadori et al., 1999, Lee et 
al., 2011, Bender et al., 2015, Mosberg et al., 2013), and alkaloid (Anathan et al., 1999, Anathan 
et al., 2004, Horan et al., 1993, Healy et al., 2013) compounds have been described. Noteworthy 
ligands are the peptides DIPPψNH2 (Schiller et al., 1999) and VRP26 (Anand et al., 2016), the 
bivalent ligand MDAN-21 (Lenard et al., 2007), and the multifunctional opioid alkaloid 
UMB425 (Healy et al., 2013). All show some improvement over morphine, but both DIPPψNH2 
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and UMB425 produce significant tolerance and dependence after chronic administration, and 
MDAN-21 was effective in some (Aceto et al., 2012, Daniels et al., 2005), but not all (Aceto et 
al., 2012), measures of antinociception. We previously reported that VRP26 produces no 
antinociceptive tolerance or physical dependence after seven day continuous administration and 
produces little conditioned place preference (Anand et al., 2016); however, VRP26 is difficult to 
synthesize and purify and therefore makes a poor drug candidate. While these µ-receptor 
agonist/δ-receptor antagonist compounds display promising effects in vivo, there is still room for 
improvement.  
We have previously described a series of peptidomimetics which display µ-receptor 
agonist/δ-receptor antagonist characteristics in vitro and produce opioid-mediated 
antinociception in vivo after peripheral administration (Bender et al., 2015, Harland et al., 2015, 
Mosberg et al., 2013). In this report, we evaluated the acute and chronic effects of these 
compounds after repeated escalating doses for five days and the role of δ-receptor in the 
development of µ-receptor-mediated tolerance and dependence. 
 
METHODS 
In Vitro Characterization of Compounds: 
Cell Lines and Membrane Preparations: C6-rat glioma cells stably transfected with a rat μ (C6- 
µ-receptor) or rat δ (C6- δ-receptor) opioid receptor (Lee et al., 1999) and Chinese hamster ovary 
(CHO) cells stably expressing a human κ (CHO-κR) opioid receptor (Husbands et al., 2005) 
were used for all in vitro assays. Cells were cultured and membranes prepared as previously 
described (Anand et al., 2012). 
Radioligand Binding Assays: Radioligand binding assays were performed as previously 
described (Anand et al., 2012). In brief, assays were performed using competitive displacement 
of 0.2 nM [3H]diprenorphine (250 µCi, 1.85TBq/mmol) by the test compound from membrane 
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preparations containing opioid receptors. The assay mixture, containing membranes 
(approximately 20 μg protein/tube) in 50 mM Tris-HCl buffer (pH 7.4), [3H]diprenorphine, and 
various concentrations of test compound, was incubated on a shaker at room temperature for 1 h 
to allow binding to reach equilibrium. The samples were filtered through Whatman GF/C filters 
and washed five times with 50 mM Tris-HCl buffer (pH 7.4). The radioactivity retained on dried 
filters was determined by liquid scintillation counting after saturation with EcoLume liquid 
scintillation cocktail in a Wallac 1450 MicroBeta (Perkin-Elmer, Waltham MA, USA). 
Nonspecific binding was determined using 10 μM naloxone. The results presented are the mean 
± SEM from three individual assays performed on three different days. Each individual assay is 
performed in duplicate and then averaged.   
Radioligand Binding Assays in Sodium. Binding assays were performed by competitive 
displacement of [3H]diprenorphine (250 μCi, 1.85 TBq/mmol) by test compound. The assay 
mixture contained the following components: assay buffer (50 mM Tris-HCl, 100 mM NaCl, 5 
mM MgCl2, 1 mM EDTA, pH 7.4), various concentrations of test compound diluted in buffer, 
0.2 nM [3H]diprenorphine and membrane preparations containing opioid receptors 
(approximately 20 μg protein/tube) supplemented with 10 μM GTPγS.  Nonspecific binding was 
determined using 10 μM naloxone.  The assay plate was incubated at room temperature on a 
shaker for 75 min to allow binding to reach equilibrium. The mixture was then vacuum filtered 
through Whatman GF/ C filters using a Brandel harvester (Brandel; Gaithersburg, MD, USA) 
and washed 5 times with 50 mM Tris-HCl buffer. Retained radioactivity was measured as 
described above.  The results presented are the mean ± SEM from three individual assays 
performed on three different days. Each individual assay is performed in duplicate and then 
averaged.   
Stimulation of GTPγ[35S] Binding: Agonist stimulation of [35S] guanosine 5'-O-[gamma-
thio]triphosphate ([35S]GTPγS, 1250 Ci, 46.2TBq/mmol) binding was measured as described 
previously (Anand et al., 2012).  Briefly, membranes (10-20 μg of protein/tube) were incubated 1 
h at room temperature in GTPγS buffer (50 mM Tris-HCl, 100 mM NaCl, 5 mM MgCl2, pH 7.4) 
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containing 0.1 nM [35S]GTPγS, 30 μM guanosine diphosphate (GDP), and varying 
concentrations of test compound. Test compound stimulation of [35S]GTPγS was compared with 
10 μM standard compounds [D-Ala2, N-MePhe4, Gly-ol]-enkephalin  (DAMGO) at µ-receptor 
and D-Pen2,5- enkephalin (DPDPE) at δ-receptor. The reaction was terminated by rapidly 
filtering through GF/C filters and washing ten times with GTPγS buffer and retained 
radioactivity was measured as described above. The results presented are the mean ± SEM from 
three individual assays performed on three different days. Each individual assay is performed in 
duplicate and then averaged; maximal stimulation was determined using nonlinear regression 
analysis to fit a logistic equation to the competition binding.  
Determination of Ke: Agonist stimulation of [35S]GTPγS binding by the known standard agonist 
DPDPE at δ-receptor was measured as described above. This was then compared to [35S]GTPγS 
binding stimulated by DPDPE in the presence of test compound. Both conditions produced 100% 
stimulation relative to DPDPE. The difference between the EC50 of DPDPE alone and in the 
presence of test antagonist is the shift in dose response. The Ke was then calculated as Ke = 
(concentration of compound)/ (Dose response shift – 1). The results presented are the mean ± 
SEM from three individual assays performed on three different days. Each individual assay is 
performed in duplicate and then averaged; maximal stimulation was determined using nonlinear 
regression analysis to fit a logistic equation to the competition binding data.  
Calculation of relative efficacy at µ-receptor. Agonist efficacy was calculated based on the 
ability to stimulate [35S]GTPγS according to the equation: efficacy = 0.5×(Emax,test /Emax,std)×(1 
+(Kitest/EC50test)),  where Emax,test is the maximum stimulation by test agonist, Emax,std is the 
maximum stimulation by DAMGO, Kitest is the affinity of test agonist in buffer containing 
sodium, and EC50test is the potency of test agonist. Hill slopes for all of the binding and 
functional data were not significantly different from one, allowing use of the Ehlert equation 
(Quock et al., 1999). 
Data Normalization. Data for all in vitro competition binding assays are normalized such that 
basal (in the presence of 10 µM naloxone) and total binding (in the absence of any drug) are set 
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to zero and 100 percent binding respectively. Data for all in vitro [35S]GTPgS assays are 
normalized such that basal (in the absence of drug) and total (in the presence of  10 µM standard 
agonist) are set to zero and 100 percent stimulation respectively. This normalization is used to 
account for variation between membrane preparations or assays. 
 
In Vivo Characterization of Compounds: 
Drug preparation. All compounds were administered by intraperitoneal (ip) or subcutaneous (sc) 
injection in a volume of 10 mL/kg of body weight. Morphine sulfate, AMB47 trifluroacetic 
acid salt (TFA), AMB46 TFA, and naltrexone HCl (NTX; Tocris, Biosciences, Minneapolis, 
MN, USA) were dissolved in sterile saline (0.9% NaCl w/v). AAH8 TFA was dissolved in 
10:10:80 ethanol:Alkamuls 620 (Solvay, St. Louis, MO, USA):sterile water. SNC80 was 
dissolved in 1 M HCl and brought to a final concentration of 3% HCl (v/v) with sterile water. 
Naltrindole HCl (NTI; Tocris, Biosciences, Minneapolis, MN, USA) was prepared in sterile 
water. 
Animals. Male and female C57BL/6 δ-receptor knockout mice (B6.129S2-Oprd1tm1Kff/J stock 
number 007557, Jackson Laboratory, Sacramento CA, USA) and their wildtype littermates, 
C57BL/6 µ-receptor knock out mice (B6.129S2-Oprm1tm1Kff/J stock number 007559, Jackson 
Laboratory, Sacramento CA, USA), or C57BL/6 wildtype mice (Stock number 000664, Jackson 
Laboratory, Sacramento CA, USA) weighing between 20-30g at 8-16 weeks old, were used for 
behavioral experiments. Knockout animals were bred in-house from heterozygous breeding pairs 
or trios. Mice were group-housed with a maximum of 5 animals per cage in clear polypropylene 
cages with corn cob bedding and nestlets as enrichment. Mice had free access to food and water 
at all times, except during measurements of fecal boli production. Animals were housed in 
pathogen free rooms maintained between 68-79°F and humidity between 30-70% humidity with 
a 12h light/dark cycle with lights on at 7:00 AM. Experiments were conducted in the housing 
room during the light cycle. Each mouse was used in only one experiment either for acute 
antinociception, tolerance, physical dependence, tail suspension test (TST), conditioned place 
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preference, or measurement of constipating effects. C57BL/6 mice are the background strain for 
all the genetic knockout strains used in this study. C57BL/6 mice were used for all studies as this 
species is commonly used in pharmacological and behavioral research. Studies were performed 
in accordance with US National Research Council's Guide for the Care and Use of Laboratory 
Animals (Council, 2011) and the ARRIVE guidelines (Kilkenny et al., 2010). For 
antinociception and constipation assays, experiments were not blinded to drug conditions due to 
the complication of multiple drug doses required for escalating doses. However, there were 
limited a priori expectations for drug effects as most compounds tested are novel entities. 
Antinociception. Antinociceptive effects were evaluated in the mouse WWTW assay. 
Withdrawal latencies were determined by briefly placing a mouse into a cylindrical plastic 
restrainer and immersing 2-3 cm of the tail tip into a water bath maintained at either 50°C or 
55°C.  The latency to tail withdrawal or rapidly flicking the tail back and forth was recorded with 
a maximum cutoff time of 20 sec (50°C) or 15 sec (55°C) to prevent tissue damage; baseline 
latencies were consistent for each assay: 3-5 sec for 50°C and 2-3 sec for 55°C.  
Acute antinociceptive effects were determined using a cumulative dosing procedure (n=6 
animals per treatment group). Each mouse received an injection of saline ip and then 30 min later 
baseline withdrawal latencies were recorded, mice were then given an ip injection of either saline 
or 1 mg kg-1 naltrexone (NTX) and withdrawal latencies recorded 30 min later. Following 
baseline determinations, cumulative doses of the test compound were given ip at 30 min 
intervals. Thirty min after each injection, the tail withdrawal latency was measured as described 
above.  
For antinociceptive tests, agonist-stimulated antinociception is expressed as a percentage of 
maximum possible effect (% MPE), where % MPE = (post-drug latency−baseline latency) ÷ 
(cutoff latency − baseline latency) × 100. Data are normalized to illustrate the difference in ED50 
values as basal and maximal values vary based on temperature. Experiments were run by two 
separate individuals across multiple days.  
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Tolerance experimental design. Antinociceptive dose effect curves for AAH8 (n=12), AMB46 
(n=12), AMB47 (n=12) and morphine (n=12) were established on the morning of Day 1 in 
wildtype C57BL/6 mice using the 50°C WWTW assay described above. Each group was then 
randomly divided such that 6 mice were assigned to receive repeated drug injections and 6 mice 
were assigned to receive repeated saline injections.  
On the morning of day 1 a dose response curve for the test compound was established up to 10 
mg kg-1 ip, and mice were then given an injection of 10 mg kg-1 test compound ip at 7 pm on the 
evening of day 1. For the remainder of the experiment mice were given twice daily injections at 
7 am and 7 pm; an escalating drug regimen was used such that mice received 20 mg kg-1 test 
compound twice daily (BID) on day 2, 30 mg kg-1 test compound BID on day 3, 40 mg kg-1 test 
compound BID on day 4, and 50 mg kg-1 test compound BID on day 5. Cumulative dose/effect 
curves were established for all mice on the morning of day 6 for their respective test compounds. 
Data are presented as mean ± SEM for each treatment group before and after repeated treatment.   
To determine agonist potency before and after repeated treatment with drug or vehicle, dose-
response curves and ED50 values were calculated for each mouse and then averaged within each 
chronic treatment group. To calculate ED50 values for each mouse in the warm water tail 
withdrawal assay, the 50% level of maximum effect was determined from a linear regression 
analysis of individual latency to tail flick data, using only the linear portion of the curve and 
including only one dose that produced <10% of the baseline latency and one dose that produced 
>90% of the maximum latency (Jutkiewicz et al., 2011). ED50 values from each mouse were then 
averaged for each treatment group (mean ± SEM). Statistical comparisons in ED50 values were 
made using a repeated measures, factorial ANOVA for each compound. 
In a separate experiment antinociceptive dose response curves for morphine were established 
using the mouse WWTW assay in δ-receptor knockout mice (n=6) and their wildtype littermates 
(n=6). Mice were given twice daily escalating doses of morphine and dose response curves pre- 
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and post-escalating doses were performed as described above. Experiments were run by two 
separate individuals across multiple sessions.  
Physical dependence experimental design. Wildtype C57BL/6 (n=6) or δ-receptor KO (n=6) 
mice were treated for 5 days with either saline or escalating doses of test compound twice daily 
as described above. On the morning of day 6, mice were given 50 mg kg-1 test compound, 
morphine, or saline ip, then returned to their home cages. Two hours later, mice were given 10 
mg kg-1 naltrexone ip and placed individually in clear plastic observation cages (10 in X 6 in X 8 
in) without bedding. Mice were observed for jumps as a sign of opioid withdrawal for 30 min 
after naltrexone injection. Statistical comparisons of the number of jumps recorded were 
assessed using a one way ANOVA. Experiments were run by two separate individuals across 
multiple sessions.  
Tail Suspension Test (TST). Mice were pretreated with either vehicle (n=6), 3.2 mg kg-1 
naltrindole (NTI; n=6), a single dose (1-10 mg kg-1) of test compound (n=6 per dose), or 10 mg 
kg-1 morphine (n=6) sc either 30 min prior to injection of 3.2 mg kg-1 SNC80 or vehicle sc. 
Thirty minutes after SNC80 (or vehicle) injection, mice were suspended by their tail from a 
height of ~40 cm using tape for 6 minutes and behavior was recorded using a Sony HDR-CX220 
digital camcorder. Videos were scored by observers blind to the test condition and the total time 
mice spent immobile was summed for each animal and then averaged within each treatment 
group. Immobility was defined as the animal remaining motionless or making only minor, non-
escape related movements. Statistical comparisons in immobility were made using a two way 
ANOVA. TST videos were scored by a separate individual who did not run the assay and was 
blinded to experimental conditions. 
Conditioned place preference and locomotor activity.  
Apparatus. A two compartment place conditioning apparatus (MedAssociates, Inc. St. Albans, 
VT) was used for all conditioned place preference (CPP) studies. The compartmentalized box 
was divided into two equal size sections (8 in x 5 in x 5 in), accessed through a single, manual, 
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guillotine door. The compartments differed in the wall color and floor texture (black walls with 
rod flooring vs. white walls with mesh flooring). Time spent in each chamber, number of beam 
breaks (used as a measure of locomotor activity), and number of entrances to each side were 
recorded using infrared photobeam detectors.  
Conditioned place preference protocol.  Experiments consisted of three phases: bias evaluation 
(2 days), conditioning (5 days), and testing (1 day).  
Bias evaluation of CPP. Wildtype mice were placed randomly into one chamber on day 1 and the 
opposite chamber on day 2 and then allowed to freely explore the apparatus for 30 min. If mice 
exhibited a greater than 70% pre-conditioning compartment bias they were discarded from the 
study; no mice were discarded based on this criterion.  
Conditioning phase of CPP. Mice were randomly assigned to be conditioned with either 10 mg 
kg-1 AAH8 (n=6), 10 mg kg-1 morphine (n=6) or saline (n=6) in either the black or white 
chamber. During conditioning mice were given a saline injection (ip) and immediately placed in 
the saline-paired chamber for 30 min; 6 h later mice were given an injection of either AAH8, 
morphine, or saline (ip) and immediately placed in the drug-paired chamber for 30 min. During 
all conditioning sessions, movement and activity were recorded. 
Test day of CPP. Test day was always performed the day after the final conditioning session. 
Mice were randomly placed in either compartment and allowed to roam freely for 30 min. No 
injection was given on test day. Time spent in each chamber, beam breaks, and entrances to each 
side were recorded. CPP scores were calculated as the difference between time spent on the 
drug-paired side on test day and the average of time spent on the future drug-paired side on the 
two bias evaluations.  
Experiments were run by two individuals across multiple sessions.  
Measurement of Fecal Bolus Production. Tinted food was prepared by combining 25g of regular 
chow with 40 mL of water and 0.25 mL of blue food dye. The food pellets were allowed to 
This article is protected by copyright. All rights reserved.
13 
 
soften (approximately 2 h) and were mixed so that the food coloring was evenly distributed 
through the food paste. Mice were given 24 h access to tinted chow 1 week prior to an 
experiment in order to habituate them to the novel food preparation and then returned to regular 
chow. For experiments mice were single housed in cages free of bedding and were food deprived 
overnight; mice had ad lib access to water for the duration of the experiment. In the morning of 
the experiment, mice were given free access to tinted chow for 1 h. The tinted food was then 
removed, the cages wiped down, and the mice were given an injection of either drug or vehicle 
ip and access to approximately 3 g of normal chow for the remainder of the experiment. The 
weight of both the normal chow and the tinted chow was recorded both before and after the 
experiment. The time to first tinted fecal bolus and the number of tinted fecal boli were recorded 
every hour for 6 h.  
Experiments were run by two individuals across multiple sessions.  
Data and Statistical Analysis 
Data analysis was performed using GraphPad Prism version 6.02 (GraphPad, San Diego, CA) or 
SPSS v22 with Tukey post-hoc tests to correct for multiple comparisons. Ki and EC50 values 
were calculated using nonlinear regression analysis to fit a logistic equation to the competition 
binding data. ED50 values were calculated using GraphPad Prism version 6.02 by extrapolating 
the 50% maximum effect from the straight line analysis of the individual dose effect curves 
(Jutkiewicz et al., 2011) and then ED50 values were averaged within treatment group. For in vivo 
experiments, 6 mice per experimental condition (e.g., per drug and per genotype) were used. For 
statistical tests, post hoc tests were run only when F achieved P<0.05 (α level was set to 0.05). 
There was no exclusion of any data in any studies. Treatment conditions were randomized across 
cages of mice and across at least 3 independent experiments. For in vivo studies, power analysis 
(α=0.05; 1-β=0.9) revealed that for a calculated effect size of 1-3 (Cohen’s d), depending on the 
experiment, that a sample size of 4-6 mice per experimental condition would be needed 
(G*Power 3.1.9.2, Faul et al., 2007). The data and statistical analysis comply with the 
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recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015).  
Materials: All reagents and solvents were purchased from commercial sources and used without 
further purification. All chemicals and biochemicals were purchased from Sigma Aldrich (St. 
Louis, MO, USA) or Fisher Scientific (Hudson, NH, USA), unless otherwise noted.  All tissue 
culture reagents were purchased from Gibco Life Sciences (Grand Island, NY, USA). 
Radioactive compounds were purchased from Perkin-Elmer (Waltham, MA, USA). 
Synthesis. AAH8, AMB46 and AMB47 using the route previously described (Bender et al., 
2015, Harland et al., 2015).  
Nomenclature of Targets and Ligands Key protein targets and ligands in this article are 
hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common 
portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018), and 
are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et 
al., 2017). 
 
RESULTS 
In Vitro Results 
Affinity. As previously reported, AAH8 (Harland et al., 2015), AMB47, and AMB46 (Bender et 
al., 2015) all display low nanomolar binding affinity for µ-receptor and δ-receptor when binding 
assays are conducted in Tris buffer. Morphine, a prototypical µ-receptor ligand, binds with low 
nanomolar affinity to µ-receptor, preferring µ-receptor 50-fold over δ-receptor (Table 1). As it 
has been demonstrated that sodium ions can alter the affinity of opioid ligands for their receptors 
(Simon and Groth, 1975, Pert et al., 1973, Selley et al., 2000), we assessed the affinity of AAH8, 
AMB47, AMB46, and morphine for µ-receptor and δ-receptor in the presence of sodium. 
Sodium ions decrease the affinity at µ-receptor and δ-receptor for all compounds tested, though 
the fold change in affinity is different for different compounds at each receptor (Table 1). 
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Efficacy. AAH8, AMB47, and AMB46 are full agonists in the [35S]GTPγS assay at the µ-
receptor as compared with DAMGO, with low nanomolar EC50 values; morphine is a partial 
agonist as compared with DAMGO. The relative efficacy of these compounds in vitro is as 
follows: AAH8>AMB46>AMB47>morphine. AAH8 AMB47, and AMB46 are antagonists at 
the δ-receptor as they attenuate DPDPE-stimulated [35S]GTPγS binding, with antagonist potency 
values (Ke) values in the nanomolar range; in this assay, NTI, a known δ-receptor antagonist, 
displays a Ke value of 0.13 ± 0.03 nM. Morphine is a low-affinity, partial agonist at the δ-
receptor and as such does not shift the dose response curve for DPDPE and does not produce a 
measurable Ke value in vitro (Table 1). 
In Vivo Results 
 µ-Receptor-Mediated Acute Antinociceptive Effects. The antinociceptive effects of AAH8, 
AMB47, AMB46, and morphine were assessed using the 50ºC warm water tail withdrawal 
(WWTW) assay in wildtype C57BL6/J mice pretreated with either saline or 1 mg kg-1 naltrexone 
(NTX), a non-selective opioid antagonist, to determine if antinociceptive effects are opioid-
mediated in vivo. Consistent with earlier results (Bender et al., 2015, Harland et al., 2015), all 
compounds produce maximal antinociceptive effects at 10 mg kg-1 after ip injection in mice 
pretreated with saline (Figure 1). Pretreatment with 1 mg kg-1 NTX ip produces an approximate 
3-fold parallel rightward shift in the dose response curves for AAH8, AMB47, AMB46, and 
morphine (Table 2). All compounds were then tested in µ-receptor knockout mice, to determine 
if the antinociceptive effects were µ-receptor-mediated. Consistent with in vitro results, neither 
the test peptidomimetics nor morphine produced any antinociception in µ-receptor knockout 
mice (Figure 1); ethylketocyclazocine, a known κ-receptor agonist (used as a positive control) 
produced dose-dependent antinociception (Supplemental Figure 1). 
While the peptidomimetics are equipotent in the 50°C WWTW assay, when tested at 55ºC, 
differences in ED50 between the compounds are observed even though they are all still fully 
effective (Figure 1; Table 2). A one way ANOVA of ED50 values (F(3,40) = 398.9) shows a 
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main effect of drug, demonstrating that AAH8 and morphine are significantly more potent than 
either AMB47 or AMB46 (F (3,40) = 41.8).  
In Vivo Acute δ-receptor Antagonist Effects. To investigate whether AAH8, AMB47, and 
AMB46 function as centrally-active δ-receptor antagonists in vivo, we examined their ability to 
block the antidepressant-like effects of a δ-receptor agonist, SNC80, in the tail suspension test 
(TST) as compared with the prototypic δ-receptor antagonist naltrindole (NTI; Figure 2A). A 
two way ANOVA of the data shows a significant main effect of SNC80 dose (F(1,30) = 101.1) 
and of pretreatment (NTI, morphine or vehicle, F (2,30) = 45.83), and an interaction of 
pretreatment X SNC80 dose (F(2,30) = 14.10). Mice treated with 3.2 mg kg-1 SNC80 (sc) alone 
display a significant decrease in immobility as compared with vehicle treated mice. This SNC80-
induced decrease in immobility is blocked by pretreatment with 3.2 mg kg-1 NTI (sc); NTI 
pretreated mice have immobility scores that are not statistically different from immobility scores 
in vehicle-treated mice. Pretreatment with morphine produces small, though not statistically 
significant, decreases in immobility scores in vehicle-treated mice.  
δ-receptor antagonist dose response curves were established for AAH8, AMB47, and AMB46 as 
pretreatments to SNC80 (Figure 2B). One way ANOVAs were performed for each 
peptidomimetic dose response curve in the mouse TST comparing each dose to SNC80 alone and 
peptidomimetic alone (control conditions); all three one way ANOVAs showed a significant 
effect of treatment: AAH8 F(4, 25) = 12.88, AMB47 F(5, 30) = 36.47, and AMB46 F(5, 30) = 
24.62. The large dose of each peptidomimetic alone (10 mg kg-1) produces immobility levels 
similar to that observed with no drug conditions (Figure 2A) and SNC80 alone significantly 
decreases immobility. Mice pretreated with the smallest doses tested of AAH8 (1 mg kg-1), 
AMB47 (0.32 mg kg-1), and AMB46 (0.32 mg kg-1) display immobility scores similar to those 
produced by SNC80 alone. However, pretreatment with larger doses of AAH8 (3.2 and 10 mg 
kg-1), AMB47 (1, 3.2, and 10 mg kg-1) and AMB46 (1, 3.2, and 10 mg kg-1) prior to SNC80 
significantly attenuates SNC80-induced decreases in immobility, and these scores are not 
statistically different from treatment with peptidomimetic alone. IC50 values derived 
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peptidomimetic dose effect curves show that AAH8, AMB47, and AMB46 have similar δ-
receptor antagonist potencies in vivo (IC50 2.06 mg kg-1, 1.66 mg kg-1, and 1.61 mg kg-1 
respectively). NTI is reported to have an IC50 of 2 mg kg-1 in the mouse TST in male C57BL6 
mice (Naidu et al., 2007).  
Development of Tolerance to Antinociceptive Action. 
AAH8. A factorial ANOVA of the AAH8 dose effect curves before and after repeated treatment 
shows no interaction between factors (AAH8 dose X day X repeated treatment). There is a main 
effect of AAH8 dose (F(4,40) = 510.28), demonstrating that AAH8 produces dose-dependent 
increases in antinociceptive effects, but there is no effect of day (day 1 vs day 6) or repeated 
treatment (saline vs AAH8). A separate two way, repeated measures ANOVA of the ED50 values 
only also demonstrates that there is no significant shift in the dose response curves for AAH8 
before and after repeated treatment in either saline or AAH8 treated groups (day 1 saline treated 
group: 4.73 ± 0.002 mg kg-1, day 1 AAH8 treated group: 4.74 ± 0.02; day 6 saline treated group: 
4.73 ± 0.002 mg kg-1, day 6 AAH8 treated group: 4.74 ± 0.0001; Figure 3A).  
AMB47. Similar to AAH8, a factorial ANOVA of the AMB47 dose effect curves before and 
after repeated treatment shows no interaction between factors (AMB47 dose X day X repeated 
treatment). There is a main effect of AMB47 dose (F(4,40) = 1129.71), demonstrating that 
AMB47 produces dose-dependent increases in antinociceptive effects, but there is no effect of 
day (day 1 vs day 6) or repeated treatment (saline vs AMB47). A separate two way, repeated 
measures ANOVA of the ED50 values also demonstrates that there is no significant shift in the 
dose response curves for AMB47 before and after repeated treatment in either saline or AMB47 
treated groups (day 1 saline treated group: 4.73 ± 0.19 mg kg-1, day 1 AMB47 treated group: 
4.64 ± 0.09, day 6 saline treated group: 4.95 ± 0.24 mg kg-1, day 6 AMB47 treated group 4.73 ± 
0.14; Figure 3B).  
AMB46. A factorial ANOVA comparing AMB46 dose effect curves before and after repeated 
treatment shows a significant interaction (AMB46 dose X day X repeated treatment; F(4,40) = 
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23.245) and significant main effects of AMB46 dose (F(4,40) = 1096.44), day (1 vs 6 F(1,10) = 
12.71), and repeated treatment (saline vs AMB46, F(1,10) = 8.60). Repeated treatment with 
AMB46, but not saline, produces a 3-fold, rightward, parallel shift in the AMB46 dose response 
curve (repeated treatment X day interaction F(1,10) = 51.71). After 5 days of treatment with 
escalating doses of AMB46, the ED50 of the AMB46 dose effect curve is more than 3.5-fold 
larger on day 6 (17.04 ± 1.25 mg kg-1) as compared with day 1 (4.63 ± 1.06 mg kg-1). The 
AMB46 dose effect curves in mice treated with saline are not different on day 1 and 6 (day 1: 
5.18 ± 0.31 mg kg-1 vs day 6: 4.73 ± 0.006 mg kg-1). A separate two way, repeated measures 
ANOVA of the ED50 values shows significant main effects of repeated treatment (F (1, 10) = 
78.25) and day (F (1, 10) = 89.68)), and an interaction of repeated treatment X day (F (1, 10) = 
103.8; Figure 3C). 
Morphine. A factorial ANOVA comparing morphine dose effect curves before and after repeated 
treatment shows a significant interaction (morphine dose X day X repeated treatment; F(4,40) = 
25.07) and significant main effects of morphine dose (F(4,40) = 1008.61), day (1 vs 6; F(1,10) = 
51.62), and repeated treatment (saline vs morphine; F(1,0) = 35.71). Repeated morphine, but not 
repeated saline, treatment produces a 3-fold, rightward, parallel shift in the morphine dose 
response curve (treatment X day interaction F(1,10) = 31.79). After 5 days of treatment with 
escalating doses of morphine, the ED50 of the morphine dose effect curve is more than 3-fold 
larger on day 6 (14.72 ± 1.39 mg kg-1) as compared with day 1 (4.74 ± 0.11 mg kg-1, F(1,10) = 
9.881). The morphine dose effect curves in mice treated with saline are not different on day 1 
and 6 (day 1: 4.93 ± 0.32 mg kg-1 vs day 6: 4.53 ± 0.26 mg kg-1). A separate two way, repeated 
measures ANOVA of ED50 values shows a significant effect of repeated treatment (F (1, 10) = 
45.56) and day (F (1, 10) = 44.96)), and an interaction of chronic treatment X day (F (1, 10) = 
52.83; Figure 3D). 
δ-receptor knockout mice and their wildtype littermates.  
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A factorial ANOVA comparing morphine dose effect curves in δ-receptor knockout mice and 
their wildtype littermates before and after repeated morphine treatment shows a significant 
interaction (morphine dose X day X genotype; F(4,40) = 32.89) and significant main effects of 
morphine dose (F(4,40) =  962.39), day tested (1 vs 6; F(1,10) = 4.14), and genotype (δ-receptor 
knockout vs wildtype; F(1,0) = 46.03). Repeated morphine administration in wildtype mice, but 
not δ-receptor knockout mice, produces a 3-fold, rightward, parallel shift in the morphine dose 
response curve (genotype X day interaction F(1,10) = 33.28). After repeated treatment with 
escalating doses of morphine, the ED50 of the morphine dose effect curve in wildtype littermates 
is 3-fold larger on day 6 (14.73 ± 0.79 mg kg-1) as compared with day 1 (4.63 ± 0.26 mg kg-1). 
The morphine dose effect curves in δ-receptor knockout mice are not different on day 1 and 6 
(day 1: 4.73 ± 0.13 mg kg-1 vs day 6: 4.74 ± 0.24 mg kg-1; Figure 5A). A separate two way, 
repeated measures ANOVA of ED50 values shows a significant effect of genotype (F (1, 10) = 
196) and day (F (1, 10) = 97.9)), and an interaction of chronic treatment X day (F (1, 10) = 97.8). 
Physical Dependence. 
In wildtype mice treated repeatedly with increasing doses of morphine, AMB47, or 
AMB46 for five days, naltrexone precipitates jumping behavior (one way ANOVA (F(4,25) = 
8.15; Figure 4). In morphine and AMB46 treated mice, naltrexone elicits significantly more 
jumps than in mice treated with saline or AAH8. The number of naltrexone-precipitated jumping 
in AMB47 treated mice is significantly larger than in saline treated mice, but not AAH8 treated 
mice. There is no difference between mice treated chronically with saline or AAH8. After five 
days of escalating morphine doses, naltrexone precipitates a similar number of withdrawal jumps 
in δ-receptor knockout mice and wildtype littermates (Figure 5B). 
Conditioned Place Preference. The rewarding effects of both morphine and AAH8 were 
explored using the conditioned place preference (CPP) assay (Figure 6A; one way ANOVA (F 
(2, 15) = 6.382)). Conditioning with morphine produces a significant increase in time spent on 
the morphine-paired side of the apparatus as compared with conditioning with saline or AAH8 
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(Figure 6A). Conditioning with AAH8 does not increase time spent on the AAH8-paired side of 
the apparatus as compared to saline conditioning. 
Locomotor activity was recorded during all conditioning sessions. A two way, repeated 
measures ANOVA shows a significant main effect of drug (F(2,15) = 12.10), but no effect of day 
and no significant interaction. Morphine produces a significant increase in locomotor activity as 
compared with saline on both day 1 and day 5. AAH8 does not increase locomotor activity on 
either day 1 or day 5 (Figure 6B). 
Production of Fecal Boli. Mice treated with saline produce significantly more tinted fecal boli 
than those treated with AAH8, AMB47, AMB46, or morphine (one way ANOVA F(4,27) = 
30.77; Figure 7), and there was no difference in number of tinted fecal boli between mice treated 
with AAH8, AMB47, AMB46, and morphine. A one way ANOVA shows that mice treated with 
saline produced tinted fecal boli significantly earlier than those treated with AAH8, AMB47, 
AMB46, or morphine (one way ANOVA F(4,35) = 49.14; Supplementary Figure 1). The time to 
first tinted fecal bolus is not statistically different in mice treated with AAH8, AMB47, AMB46, 
and morphine (Supplementary Figure 1). 
 
DISCUSSION and CONCLUSIONS 
The data described in this report demonstrate that the structurally-related, mixed efficacy 
opioid ligands AAH8, AMB47 and AMB46 produce similar effects in vivo after acute 
administration but have different profiles of activity following repeated administration. 
Consistent with their in vitro profile, these compounds act as µ-receptor agonists and δ-receptor 
antagonists in vivo (Figures 1 and 2). They produce dose-dependent antinociceptive effects with 
similar potencies and are fully effective, as compared with morphine, in the 50ºC WWTW assay. 
Naltrexone attenuates the antinociceptive effects to a similar extent as shown by equivalent shifts 
in their ED50s (Table 2), suggesting that these antinociceptive effects are opioid receptor-
mediated. Further, the antinociceptive effects of these peptidomimetics are completely attenuated 
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in µ-receptor knockout mice, demonstrating that the antinociception is µ-receptor-mediated 
(Figure 1). Doses that are fully effective in a 50ºC WWTW assay also decrease the production of 
fecal boli produced over a 6 hour window (Figure 7), consistent with the effects of morphine. As 
δ-receptor antagonists, these compounds attenuate SNC80-induced decreases in immobility in 
the mouse TST (Figure 2) with IC50s similar to NTI (Naidu et al., 2007). These compounds may 
be slightly less effective than the known δ-receptor antagonist NTI, which could be due to their 
µ-receptor agonist activity, consistent with the small, non-significant decreases in immobility 
produced by morphine alone (Figure 2). Overall, these data demonstrate that AAH8, AMB47, 
and AMB46 simultaneously function as µ-receptor agonists and δ-receptor antagonists in vivo. 
Further, the δ-receptor antagonist properties of these compounds do not alter their acute 
antinociceptive or constipating effects. 
The acute behavioral effects of these compounds are consistent with their in vitro profile 
as µ-receptor agonists. All three peptidomimetics display high affinity µ-receptor binding 
affinities in the absence of sodium. In the presence of sodium ions, the affinity of these ligands 
for µ-receptor is decreased, as expected since sodium ions stabilize inactive receptor states and 
alter agonist affinity (Pert et al., 1973, Selley et al., 2000, Simon and Groth, 1975); however, 
these compounds still have Ki values in the nanomolar range and demonstrate higher µ-receptor 
affinity than morphine under these conditions. In addition, these ligands are more efficacious 
than morphine in vitro. Consistent with this idea, their calculated relative efficacies using the 
Ehlert equation (Quock et al., 1999) can be rank ordered: AAH8>AMB46>AMB47≈morphine. 
However, these in vitro data do not effectively predict their potency and efficacy in vivo. For 
example, in a 50°C WWTW assay, these compounds demonstrate similar potency to morphine 
and produce a maximal response at similar doses, but under higher efficacy-requiring conditions 
(55°C WWTW), the dose effect curves for AMB46 and AMB47 are shifted to a greater extent 
than AAH8 and morphine. These findings would suggest that AAH8 and morphine are higher 
efficacy agonists than AMB46 and AMB47, which is not entirely consistent with their in vitro 
profile. Suggesting, some unidentified pharmacokinetic parameter may be responsible for the 
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differences between these ligands in vivo. It is possible that differential plasma protein binding, 
metabolism, or distribution to the active site, presumably the CNS, leads to different local 
concentrations of peptidomimetic, which may explain the discrepancies between in vitro and in 
vivo potencies and efficacies. Future work will explore how the pharmacokinetic properties of 
compounds in this series alters their acute and chronic effects. 
While these compounds are µ-receptor agonists in vitro, they do not stimulate δ-receptor-
mediated [35S]GTPγS binding in cells and attenuate δ-receptor agonist-stimulated G protein 
activation, suggesting they are δ-receptor antagonists. Notably, these ligands differ in their 
affinity for δ-receptor in vitro over an 80-fold range. In the absence of sodium, these ligands 
have low nanomolar or sub-nanomolar affinity for δ-receptor with a rank order of 
AAH8>AMB47>AMB46. In the presence of sodium, the rank order for affinity at δ-receptor 
does not change, but the Ki values shift, inconsistent with neutral antagonist activity. These 
findings suggest that these compounds could potentially be low efficacy δ-receptor agonists 
(below the threshold for this assay). Again, these in vitro data do not correlate well with in vivo 
δ-receptor antagonist activity, since the three peptidomimetics display similar δ-receptor 
antagonist-like activity in vivo with equivalent potency (Figure 2).  
Although these compounds have similar µ-receptor and δ-receptor activity following 
acute administration in vivo, their behavioral effects differ following repeated administration. For 
example, tolerance, as demonstrated by rightward shifts in the dose effect curves, is observed 
following repeated administration of morphine, AMB46, but not AAH8 and AMB47 (Figure 3). 
Naltrexone precipitates withdrawal in mice treated with repeated morphine, AMB46, and 
AMB47, but significantly fewer signs of withdrawal are observed in mice that receive repeated 
AAH8. Considering the in vivo effects of these 3 compounds evaluated in the current study, the 
rank order of most favorable profile is: AAH8>AMB47>AMB46≈morphine. Overall, the 
compound with the most promising profile is AAH8 since it produces less tolerance and physical 
dependence as compared with morphine under the same conditions. In addition, AAH8 also 
failed to produce conditioned place preference at a dose that produces significant antinociception 
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(Figure 6). These findings suggest that AAH8 is less rewarding than morphine and, therefore, 
may be a safer analgesic than traditional opioids.  
While this study identifies a promising candidate, it also highlights that the combination 
of a µ-receptor agonist with δ-receptor antagonist is not sufficient to prevent tolerance 
development since all of these compounds were δ-receptor antagonists in vivo. To further probe 
the disparities between these compounds in terms of tolerance development, we considered 
whether differences in 1) µ-receptor efficacy, 2) δ-receptor affinity and/or 3) µ-receptor:δ-
receptor affinity ratio would correlate with the rank order of favorable profiles 
(AAH8>AMB47>AMB46≈morphine). In terms of µ-receptor efficacy, we hypothesized that 
high efficacy µ-receptor agonists would be less likely to produce tolerance due to a larger 
receptor reserve. In vitro relative efficacy calculations at µ-receptor orders the compounds: 
AAH8>AMB46>AMB47≈morphine, but in vivo we observe a different organization under the 
higher efficacy conditions such that AAH8=morphine>AMB47=AMB46. Therefore, in vitro 
relative efficacy does not appear to predict in vivo efficacy requirement, and compound efficacy 
in vitro or in vivo does not correlate with the lack of tolerance development.   
While δ-receptor antagonist activity alone is not sufficient to prevent tolerance, it is likely 
that δ-receptor plays a significant role, as demonstrated by less tolerance development in mice δ-
receptors. Some compound properties that do correlate with the lack of tolerance development 
under these conditions include: 1) δ-receptor affinity in both binding assay conditions or as 
determined Ke values and 2) µ-receptor:δ-receptor affinity ratios, such that high affinity binding 
at δ-receptor may protect against tolerance, and possibly, dependence. However, δ-receptor 
expression and/or signaling may be less relevant to the mechanisms involved in physical 
dependence, since precipitated withdrawal is similar in wildtype and δ-receptor knockout mice. 
Future studies will probe the role of δ-receptor in the effects of chronic administration of mixed 
efficacy opioid ligands. Furthermore, a single characteristic alone may not account for the lack of 
tolerance development with some of these ligands, but multiple features may be required to 
produce some preferred pharmacological profile, such as a combination of high efficacy µ-
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receptor agonist activity and high affinity binding to δ-receptor. Still other mechanisms, not 
considered here, may be important in preventing tolerance development. For instance, activity at 
the κ-receptor may play an important role; all three peptidomimetics bind the κ-receptor  with 
nanomolar affinity and both AMB47 and AMB46 display some κ-receptor activation in the 
GTPγS assay. It is possible that chronic activation of κ-receptor  may play a role in the 
development of adverse effects associated with opioid use. Another possible factor to consider is 
that these peptidomimetics may activate distinct intracellular signaling pathways and may exhibit 
biased signaling at one or more of the opioid receptors. It has been proposed that developing 
biased µ-receptor agonists that favor G protein signaling over arrestin3 signaling might provide 
pain relief without the development of adverse effects (Kelly, 2013, Raehal et al., 2011). 
However, the loss of arrestin3 does not attenuate the development of adverse effects for all 
opioid agonists, suggesting that agonists produce adverse effect through different mechanisms or 
that other factors mediate adverse effects (Raehal and Bohn, 2011). Further, the theory is not 
supported by studies of G protein biased µ-receptor agonist TRV130 (Altarifi et al., 2017). 
Future work will explore these possibilities to determine what role, if any, they play development 
of adverse effects to opioid analgesics.  
Overall, this report identifies a promising opioid ligand that produces antinociception 
without development of tolerance or dependence under the conditions tested; further, our lead 
compound, AAH8, is less rewarding than morphine. However, it also highlights that the 
combination of a µ-receptor agonist with a δ-receptor antagonist is not sufficient to prevent the 
development of tolerance or physical dependence since all of these compounds were δ-receptor 
antagonists in vivo. Future studies will test AAH8 over longer periods of administration and in 
chronic pain models. Finally, we will continue to probe the mechanisms by which δ-receptor 
antagonist activity modifies tolerance development to µ-receptor agonists in order to better 
understand how these mixed efficacy ligands differ in their in vivo effects following repeated 
administration. 
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Table and Figure Legends: 
Table 1: Binding affinities (Ki) were obtained by competitive displacement of radiolabeled [3H] 
diprenorphine in the presence or absence of sodium chloride. Efficacy data were obtained using 
[35S]GTPγS binding assay. Efficacy is represented as percent maximal stimulation relative to 
standard agonists DAMGO (µ), DPDPE (δ) or U69,593 (κ) at 10µM concentrations. Relative 
efficacy at µ was calculated using the Ehlert equation. Ke values at δ were determined by shifting 
the dose response curve for DPDPE, a standard δ agonist. All values are expressed as mean ± 
SEM of three separate assays performed in duplicate. nd = not determined, dns = does not 
stimulate. n=3 for all experiments.  a – data previously published in Harland et al., 2015; b – data 
previously published in Bender et al., 2015 
 
Table 2: ED50 values for peptidomimetics and morphine tested in the WWTW assay with either a 
saline (50° and 55°C) or 1 mg kg-1 naltrexone (NTX; 50°C) pretreatment. ED50 values were 
calculated using a linear regression fit for the cumulative dose-response data from each 
individual mouse then averaged to get an ED50 value for each treatment group (n=6). 
 
Figure 1: Cumulative dose response curves for (A) AAH8, (B) AMB47 (C) AMB46, and (D) 
morphine in the mouse warm water tail withdrawal assay at 50°C (open symbols) or 55°C 
(closed symbols) in wildtype mice or at 50ºC in µ-receptor knockout mice (grey symbols). Data 
are plotted as mean ± SEM for all groups (n=6 for each group). 
 
Figure 2: (A) Immobility scores in the mouse TST for animals pretreated with either vehicle, 3.2 
mg kg-1 NTI, or 10   mg kg-1 morphine 30 min before 3.2 mg kg-1 SNC80. Pretreatment with NTI 
attenuates SNC80-induced antidepressant-like effects, as expected for a δ antagonist. Morphine 
does not alter SNC80s effects in the TST. # indicates significance relative to vehicle 
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pretreatment (B) Dose response curves for AAH8, AMB47, and AMB46 in the mouse TST.  * 
indicates that all peptidomimetics are significantly different from SNC80 alone, # indicates 
AMB47 and AMB46 are significantly different from SNC80 alone, & indicates that all 
peptidomimetics are significantly different from 10 mg kg-1 peptidomimetic alone, $ indicates 
that AMB47 and AMB46 are significantly different from 10 mg kg-1  peptidomimetic alone. Data 
are plotted as mean ± SEM for all groups (n=6 for each group). 
 
Figure 3: 5 days of chronic escalating treatment with AAH8 (A) or AMB47 (B) (10-50 mg kg-1 
ip, twice daily) treatment ip (n=6) produces no shift in the dose effect curve in wild type BL6 
mice. 5 days of chronic escalating morphine (D) or AMB46 (C) (10-50 mg kg-1 ip, twice daily) 
treatment ip (n=6), but not saline (n=6) produces a significant 3-fold rightward shift in the dose 
effect curve in wild type BL6 mice. * indicates significant difference relative to data from day 1. 
Data are plotted as mean ± SEM for all groups (n=6 for each group). 
 
Figure 4: Wildtype mice were treated for 5 days with either saline or escalating doses of AAH8, 
AMB47, AMB46, or morphine (10-50 mg kg-1 ip, twice daily). Withdrawal was precipitated 
with 10 mg kg-1 NTX ip and number of jumps were counted. Animals treated chronically with 
AMB47, AMB46, and morphine experienced more NTX precipitated withdrawal jumps than 
animals treated chronically with saline or AAH8. *indicates significant difference relative to 
saline, # indicates significant difference relative to AAH8. Data are plotted as mean ± SEM for 
all groups (n=6 for each group). 
 
Figure 5: (A) 5 days of chronic escalating treatment with morphine (10-50 mg kg-1 ip, twice 
daily) in δ KO mice (-/-) and their wild type littermates (+/+) produces no shift in the dose effect 
curve in δ KO mice, but produces a 3 fold rightward shift in wild type mice. (B) Wild type (+/+) 
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and δ KO (-/-) mice were treated for 5 days with escalating doses of morphine (10-50 mg kg-1 ip, 
twice daily). Withdrawal was precipitated with 10 mg/kg NTX. There was no significant 
difference in the number of jumps observed across genotype. * indicates a significant difference 
relative to data from day 1. Data are plotted as mean ± SEM for all groups (n=6 for each group). 
 
Figure 6: Conditioned place preference (CPP) scores for animals trained for 5 days on either 10 
mg kg-1 morphine, 10 mg kg-1 AAH8 or saline for 5 days ip. CPP scores are defined as the 
difference between time spent on drug paired side pre- and post- conditioning measured in 
seconds. (A) Animals conditioned with morphine spent more time on the drug paired side of the 
CPP apparatus than those trained to either AAH8 or saline. (B) Locomotor activity over 30 mins 
for 10 mg kg-1 morphine, 10 mg kg-1 AAH8 and saline on Day 1 and Day 5. Data are plotted as 
mean ± SEM for all groups (n=6 for each group). 
 
Figure 7: Acute treatment with 10 mg kg-1 AAH8, AMB47, AMB46, and morphine all 
significantly reduce the number of fecal boli produced over 6 h as compared to saline controls. 
Data are plotted as mean ± SEM for all groups (n=6 for each group). 
 
Supplemental Figure 1. Cumulative dose response curves for morphine or the κ-receptor agonist 
ethylketocyclazocine (EKC) (or repeated saline injection) in the 50ºC mouse warm water tail 
withdrawal assay at 50°C in µ-receptor knockout mice. Data are plotted as mean ± SEM for all 
groups (n=6 for each group). 
 
Supplemental Figure 2: Acute treatment with 10 mg kg-1 AAH8, AMB47, AMB46, and 
morphine all significantly increase the time to first tinted fecal bolus as compared to saline 
controls. Data are plotted as mean ± SEM for all groups (n=6 for each group). 
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Table 1
Relative 
efficacy
at µ
µ δ k
µ:δ 
Ratio
µ δ
µ:δ 
Ratio
µ % 
Stim
µ EC50 
(nM)
δ % 
Stim
δ EC50 
(nM)
k % 
Stim
k EC50 
(nM)
1.3 103 149 433 57 152 28 1200
-0.3 -4 -66 -43 -2 -36 -2 -600
0.2 50 1.7 1.1 87 0.9 1.8
(0.02) a (18) a -0.7 -0.4 (3) a (0.2) a -0.1
0.19 0.9 0.8 0.4 3.5 96 6 40 4.4
(0.08) b (0.2) b (0.1) b -0.1 -0.4 (4) b (3) b (8) b -0.4
0.15 15 2 1.6 83 96 2.6 15 15 95
(0.08)b (5) b (1) b -0.2 -11 (4) b (1.5) b (2) b (9) b -17
Ke δ 
(SEM) 
nM
Cmpd Structure Ki in Tris (SEM) nM
Ki in Tris + 100 mM NaCl 
(SEM) nM
GTPgS (SEM) 
0.56 n/a
AAH8
0.04 
(0.01) a
1:05 1:01 dnsa n/aa
Morphine 0.0965 1:03
dnsa n/aa 1.26
AMB47 1:05 1:09 dnsb n/ab >1000b 0.51
AMB46 0.1111 1:50 dnsb n/ab 0.78
HO OHO
H
N
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Table 2
Cmpd
Saline Pretreat 
(50C)
1 mg/kg NTX 
Pretreat (50C)
Saline Pretreat 
(55C)
AAH8 4.4(0.4) 13.7(1.6) 21.0 (0.8)
AMB47 5.3(0.3) 14.7(0.6) 64.5 (1.5)
AMB46 4.7(0.2) 12.9(1.5) 55.0 (1.3)
Morphine 4.7(0.05) 15.2(0.1) 16.4 (0.9)
ED50(SEM) mg/kg ip
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